No relationship between circulating levels of sex steroids and mammographic breast density: the Prospect-EPIC cohort by Verheus, Martijn et al.
Open Access
Available online http://breast-cancer-research.com/content/9/4/R53
Page 1 of 9
(page number not for citation purposes)
Vol 9 No 4 Research article
No relationship between circulating levels of sex steroids and 
mammographic breast density: the Prospect-EPIC cohort
Martijn Verheus, Petra HM Peeters, Paulus AH van Noord, Yvonne T van der Schouw, 
Diederick E Grobbee and Carla H van Gils
Julius Center for Health Sciences and Primary Care, Room Str 6.131, PO Box 85500, University Medical Center Utrecht, Utrecht 3508 GA, The 
Netherlands
Corresponding author: Carla H van Gils, c.vangils@umcutrecht.nl
Received: 8 Jun 2007 Revisions requested: 29 Jun 2007 Revisions received: 27 Jul 2007 Accepted: 13 Aug 2007 Published: 13 Aug 2007
Breast Cancer Research 2007, 9:R53 (doi:10.1186/bcr1758)
This article is online at: http://breast-cancer-research.com/content/9/4/R53
© 2007 Verheus et al.; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/
2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background High breast density is associated with increased
breast cancer risk. Epidemiologic studies have shown an
increase in breast cancer risk in postmenopausal women with
high levels of sex steroids. Hence, sex steroids may increase
postmenopausal breast cancer risk via an increase of breast
density. The objective of the present study was to study the
relation between circulating oestrogens and androgens as well
as sex hormone binding globulin (SHBG) in relation to breast
density.
Methods We conducted a cross-sectional study among 775
postmenopausal women, using baseline data of a random
sample of the Prospect-EPIC study. Prospect-EPIC is one of
two Dutch cohorts participating in the European Prospective
Investigation into Cancer and Nutrition, and women were
recruited via a breast cancer screening programme. At
enrolment a nonfasting blood sample was taken and a
mammogram was made. Oestrone, oestradiol,
dehydroepiandrosterone sulfate, androstenedione, testosterone
and SHBG levels were measured, using double-antibody
radioimmunoassays. Concentrations of free oestradiol and free
testosterone were calculated from the measured oestradiol,
testosterone and SHBG levels Mammographic dense and
nondense areas were measured using a semiquantitative
computerized method and the percentage breast density was
calculated. Mean breast measures for quintiles of hormone or
SHBG levels were estimated using linear regression analyses.
Results Both oestrogens and testosterone were inversely
related with percent breast density, but these relationships
disappeared after adjustment for BMI. None of the sex steroids
or SHBG was associated with the absolute measure of breast
density, the dense area.
Conclusion The results of our study do not support the
hypothesis that sex steroids increase postmenopausal breast
cancer risk via an increase in breast density.
Introduction
Dense breast tissues (glandular and stromal tissues) appear
light on a mammogram, while nondense tissue (fat tissue)
appears black [1]. Women with a high percentage of breast
density have been shown to have strongly increased risk for
breast cancer development [2,3].
In epidemiologic studies, nulliparity, late age at first child birth
and late age of menopause have all been related to increased
breast density, indicating that sex steroid levels may influence
breast density; it has therefore been hypothesized that breast
density may reflect lifetime exposure to sex steroids. Moreover,
postmenopausal hormone therapy (HT), and in particular com-
bination therapy of oestrogens and progesterone, increases
breast density in most women [4-7], whereas Tamoxifen, an
'anti-oestrogen', decreases breast density [8,9]. Reproductive
factors as well as HT use have been shown to have the same
positive associations with breast cancer risk as described with
breast density [10,11].
BMI = body mass index; DHEAS = dehydroepiandrosterone sulfate; EPIC = European Prospective Investigation into Cancer and Nutrition; HT = 
hormone therapy; SHBG = sex hormone binding globulin; WHR = waist–hip ratio.Breast Cancer Research    Vol 9 No 4    Verheus et al.
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Higher circulating levels of oestrogens and androgens have
been clearly established to lead to higher breast cancer risk in
postmenopausal women [12,13]. In the light of the above-
described relationships between reproductive factors and
breast density, and also exogenous hormones and breast den-
sity, one would also expect that circulating levels of endog-
enous sex steroids increase breast cancer risk by altering
breast density. Greendale and colleagues indeed showed that
women with high oestradiol levels had significantly increased
percentage breast density [14] Boyd and colleagues, how-
ever, found a statistically significant inverse relationship
between oestradiol levels and percentage density [15]. Three
other studies did not find oestrogens and breast density to be
associated [16-18]. Androgens were not related to breast
density in any of these studies, but most studies reported
higher breast density with higher sex hormone binding globulin
(SHBG) levels, which appears to contradict the inverse rela-
tion between SHBG levels and postmenopausal breast can-
cer risk shown in many studies [12,13].
Most of the studies on sex steroids and breast density were
small, however (range, 88–1413 subjects), and contained a
relatively large percentage of former HT users (range, 30–
50%). It is not known what time period is needed for a com-
plete washout of HT effects on breast tissue, and hence
results may be influenced. Furthermore, four of these studies
[14,16-18], but not that of Boyd and colleagues [15], present
results on percentage breast density only. The dense area
may, however, be a better marker of breast cancer risk than the
percentage breast density, as it is the absolute amount of glan-
dular and stromal (dense) tissue that is regarded as the target
tissue for breast cancer.
In the present large, cross-sectional study we set out to inves-
tigate the relation between circulating levels of oestrogens,
androgens and SHBG, on the one hand, and both measures
of breast density (dense area and percentage density), on the
other, in a sample of Dutch women, with very few (14%)
former HT users.
Methods
Prospect cohort
This study included women participating in Prospect-EPIC,
one of two Dutch cohorts participating in the European Pro-
spective Investigation into Cancer and Nutrition (EPIC). EPIC
is a multicentre cohort study with 10 participating European
countries. The rationale and design of both the EPIC and Pros-
pect-EPIC have been described in detail elsewhere [19-21].
The Prospect-EPIC cohort consists of 17,357 women, aged
49–69 years at enrolment. Women were recruited between
1993 and 1997 through a regional programme for breast can-
cer screening and reside in Utrecht or its vicinity. The regional
programme is part of the national screening programme that
covers the entire Dutch population. As part of the population-
based screening programme, mammographic examinations
are carried out every 2 years, starting at age 50 until age 75,
and are stored in archives.
An invitation to join the Prospect-EPIC project was mailed to
women that were invited for their routine mammography.
Those who agreed to participate subsequently received two
questionnaires by mail. A general questionnaire was used to
gather information on demographic, reproductive and lifestyle
factors and on past and current morbidity. To determine the
regular dietary intake, a validated extensive self-administered
food frequency questionnaire was used containing 178 food
items [22,23]. On the scheduled breast screening date, sub-
sequent to mammographic examination, anthropometric meas-
ures were taken and a blood sample was drawn and stored at
-196°C under liquid nitrogen.
All participants signed an informed consent and the study was
approved by The Institutional Review Board of the University
Medical Center Utrecht.
Study population
A 10% random sample (n = 1,736) was taken from the total
Prospect cohort. Mammograms of 1,595 women could be
retrieved from the archives and breast density was success-
fully measured for 1,516 women. Of these, premenopausal or
perimenopausal women or those having an unknown meno-
pausal status (n = 377) were excluded. Women with unknown
menopausal status due to hysterectomy were also excluded (n
= 257). Women with a hysterectomy after natural menopause
(n = 4) and women with ovariectomy on both ovaries were
kept in the study (n = 60). None of the 882 remaining women
were current HT or oral contraceptive users. For 775 of these
women, sex steroid and SHBG levels were available that were
used in a previous study [24]. For 98.3% of the women in the
present study, the measurement of anthropometric factors, the
mammographic examination and the blood draw were per-
formed on the same day.
Blood collection and measurements of sex steroids and 
SHBG in plasma
A 30 ml nonfasting blood sample was donated by each partic-
ipant, using three safety monovettes – one dry monovette for
serum and two citrated monovettes for plasma. Within 24
hours, samples of 4 ml serum, 9 ml citrate plasma and 2 ml
white blood cells were fractionated into 0.5 ml aliquots and
were stored in heat-sealed plastic straws under liquid nitrogen
at -196°C.
Plasma levels of oestrone, oestradiol, androstenedione, dehy-
droepiandrosterone sulfate (DHEAS), testosterone and
SHBG were measured using commercially available double-
antibody radioimmunoassay kits (Diagnostics System Labora-
tories Inc., Webster, TX, USA). The following kits were used:
oestrone, DSL-8700; oestradiol, DSL-39100; androstenedi-
one, DSL-4200; DHEAS, DSL-2700; testosterone, DSL-Available online http://breast-cancer-research.com/content/9/4/R53
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4100; and SHBG, DSL-6300. The intra-assay coefficients of
variation were 5.6%, 3.9%, 4.3%, 5.2%, 7.7% and 3.0%,
respectively. The inter-assay coefficients of variation were
11.1%, 4.1%, 6.3%, 5.3%, 8.1% and 4.0%, respectively [24].
Concentrations of free oestradiol and free testosterone were
calculated from total plasma concentrations of oestradiol, tes-
tosterone and SHBG, using theoretical calculations described
by Vermeulen and colleagues [25].
Mammographic density analysis
The mediolateral oblique mammogram, which is the routine
view for breast cancer screening in The Netherlands, was
used to assess mammographic density. The proportions of
mammographic density on craniocaudal views and medi-
olateral oblique views and on left and right views have been
observed to be very strongly correlated, and representative
information on mammographic density is provided in a single
view [26]. For each study subject, mammographic density was
assessed on the left view.
After digitizing the films using a laser film scanner (Lumiscan
50; Lumisys, Eastman Kodak Co., Rochester, NY, USA), the
mammographic density was quantified using a computer-
assisted method based on grey levels of pixels in the digitized
mammogram. This computer-assisted method to determine
mammographic density has proved very reliable, and the
method is described elsewhere in detail [1]. Briefly, for each
image, the reader first sets a threshold to determine the out-
side edge of the breast, to separate the image of the breast
from the dark background surrounding it. A second threshold
is set to determine the area of dense tissue within the breast,
which is the lightest tissue visible on the mammogram. Before
setting the thresholds, a masking tool is used to block the pec-
toralis muscle, to prevent including the pectoralis muscle in
the breast and dense areas. The program then determines the
amount of pixels within the total breast area and within the
dense area. A conversion factor of 0.000256 was used to cal-
culate the surface of the total breast area and the dense area
from the number of pixels.
To compute the percentage breast density the dense area of
a breast is divided by the total breast area and multiplied by
100. The percentage breast density is used in most publica-
tions on breast density. A small-sized breast and a larger-sized
breast, however, could have the same percentage breast den-
sity, while the absolute amount of glandular and stromal tissue,
which is regarded as the target tissue for breast cancer
[27,28], is higher in the larger breast [29]. Hence, we shall
present results for both relative and absolute measures of
breast density.
All mammograms were assessed by one observer in sets com-
posed of 35 randomly ordered films. To assess the reliability of
the reader, a library set was created, which consisted of 35
randomly chosen films from our study subjects. This library set
was read before the first set, after the last set and at four time
points between sets, which were blinded for the reader. The
images in the library set were randomly ordered every time
they were read to prevent the observer from recognizing this
set. In the present study, average intraclass correlation coeffi-
cients of 1.00 (range, 0.99–1.00), of 0.93 (range, 0.91–0.97)
and of 0.91 (range, 0.87–0.94) were reached between
repeated readings for the total breast area, the dense area and
the percentage breast density, respectively.
Statistical analyses
Subjects with plasma sex steroid or SHBG values under the
detection limit – which was 1.2 pg/ml, 1 pg/ml, 25 ng/ml, 0.02
ng/ml, 0.05 ng/ml and 5 nmol/l for oestrone, oestradiol,
DHEAS, androstenedione, testosterone and SHBG, respec-
tively – were given the value of the detection limit. Six women
had an undetectable oestrone level, five women were undetec-
table for DHEAS, eight women were undetectable for andros-
tenedione, eight women were undetectable for testosterone
and 60 women had an undetectable SHBG level. All women
had a detectable value for oestradiol. Plasma sex steroid and
SHBG levels were log-transformed to normalize the distribu-
tions. These transformed values were then used to compute
geometric mean levels.
All three measures of the breast (percentage breast density,
dense area and nondense area) were square-root-transformed
to normalize their distributions. These transformed values were
used in linear regression analyses. For ease of interpretation,
the presented means and 95% confidence intervals have been
transformed back to the original scale. Means and 95% confi-
dence intervals of breast measures by quintile level of plasma
sex steroids or SHBG were estimated with linear regression
models using the 'GLM' procedure. To test for linear trends
over the quintiles, median values within quintiles were calcu-
lated and evaluated as a continuous variable using linear
regression analysis. Potential confounding of various factors
with known association with sex steroid levels or with breast
measures, or with both, was assessed by adding those varia-
bles to the crude models.
The following characteristics were evaluated for confounding
using continuous variables: age, body mass index (BMI), waist
circumference, waist–hip ratio (WHR), age at menarche, age
at menopause, time since menopause and alcohol consump-
tion. Dichotomous variables were used for ever breast feeding
and for family history of breast cancer (mother and/or sister).
A variable for ever use of postmenopausal HT combined with
time since last use of HT was used with one category for never
users and with two categories for ever users – the first of
which contained women with a time period since last HT use
below the median (5 years), and the second contained women
with a time period since last use of the median value or greater.
Parity and age at first childbirth were evaluated using aBreast Cancer Research    Vol 9 No 4    Verheus et al.
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combined variable with one category for nulliparous women
and three categories of parous women combined with tertiles
of age at birth of the first child (tertile cutoff points, 23 and 26
years). Smoking was evaluated using a variable with three cat-
egories, for current smokers, past smokers and never smok-
ers. Variables that changed the crude associations by 5% or
more were added to the adjusted models. In a previous study
by Aiello and colleagues, different effects were found between
HT never users and ever users [16]. We therefore stratified the
analyses of all three breast measures by HT ever/never use, for
comparison.
All P values are two-sided, and results were considered signif-
icant when below 0.05. All analyses were conducted using the
Statistical Analysis System software package (release 9.1;
SAS Institute, Cary, NC, USA).
Results
Table 1 presents the basic characteristics of the study popu-
lation. The mean age at study recruitment was 60.2 years and
the mean BMI was 26.0 kg/m2. The age at first childbirth
among parous women was 25.4 years on average, and 12.8%
(n = 99) of the participants was nulliparous. Women were
aged, on average, 48.8 years at menopause, and the average
time since menopause was 11.2 years. Only 14.4% (n = 112)
of the participants had previously used HT; those previous HT
users quit using these compounds on average 7.1 years prior
to recruitment (range, 0–33 years). Median values for the per-
centage density, dense area and nondense area were 21.7%
(interquartile range, 14.9–30.8%), 25.3 cm2  (interquartile
range, 18.4–35.5 cm2) and 95.1 cm2 (interquartile range,
70.1–121.9 cm2), respectively.
The results of regression analyses for the relation between sex
steroids and the percentage breast density, the dense area
and the nondense area are presented in Tables 2, 3 and 4,
respectively. Both crude associations and associations
adjusted for variables that changed associations are pre-
sented. These variables only included BMI in the models to
calculate the mean percentage breast density and the mean
nondense area. Adding a second marker for total body fat
(WHR) to these models only had an additional effect on the
models with SHBG. The WHR was therefore added to these
models only (Tables 2 and 4 for the percentage density and
the nondense area, respectively). None of the potential con-
founders that were tested influenced associations between
sex steroids or SHBG and the dense area substantially, and
hence only the crude models are presented (Table 3).
The inverse associations of circulating levels of both oestro-
gens and testosterone with the percentage density were no
longer apparent when adjusted for BMI (Table 2). DHEAS and
androstenedione were not related to percentage density.
Women with high SHBG levels showed significantly higher
percentage density than women with low SHBG levels (Table
2). This association was still significant after correction for
BMI, but was no longer significant after further adjustment for
WHR. High oestrone levels were associated with a lower
dense area, but the relation was not statistically significant.
None of the other sex steroids or SHBG was related to the
dense area (Table 3). Before adjustment, higher levels of both
oestrogens and testosterone were significantly associated
with higher nondense area. After adjusting for BMI, however,
these associations disappeared. (Table 4). High levels of
DHEAS were borderline significantly associated with lower
nondense area, irrespective of adjustment for BMI (Table 4).
High levels of SHBG were very strongly associated with low
nondense area (Table 4). This relationship became less strong
after corrections for BMI and disappeared after additional
adjustment for WHR.
When we stratified the analyses according to HT ever use
(yes/no), results were highly comparable between the groups.
Discussion
The significant inverse associations between both oestrogens
and testosterone with percentage beast density disappeared
after adjustment for BMI. No relationships were found
between sex steroids and the absolute measure of mammo-
graphic density, the dense area. High levels of SHBG were
associated with high percentage density and a low nondense
area. These relations disappeared after corrections for BMI
and for WHR.
An advantage of the present study is its size – with 775 par-
ticipants, our study is larger than all previous studies [14-17]
except that of Warren and colleagues [18]. Another advantage
is the fact that the blood sample we used for hormone meas-
urements was drawn at the same day as mammography was
performed for most of the women (98.3%). In addition to the
measurement of total hormone levels, we also calculated free
levels of oestradiol and testosterone, because it is the
unbound hormone fraction that is expected to affect the target
(dense) tissue most clearly. The free levels used in the present
study were not directly measured but were calculated from
total plasma concentrations of oestradiol, testosterone and
SHBG, using theoretical calculations [25]. In a validation
study, Rinaldi and colleagues. showed high correlation
between measured concentrations and calculated concentra-
tions of both free oestradiol and free testosterone in
postmenopausal women (r = 0.84 and r = 0.76, respectively)
[30]. If misclassification due to measurement errors of the sex
steroids or the breast measures has occurred, this most prob-
ably has been nondifferential. This misclassification may have
led to bias to the null relation, but we do not believe this is an
explanation for the null results we found with the dense area.
To our best knowledge, seven previous studies on sex steroids
and breast density have been published [14-18,31,32], five of
which reported results on postmenopausal women [14-18].Available online http://breast-cancer-research.com/content/9/4/R53
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With the exception of the study by Boyd and colleagues [15],
all these studies reported results with the relative measure of
breast density (percentage density) only – although Aiello and
colleagues and Tamimi and colleagues mentioned that analy-
ses with absolute breast density gave similar results [16,17].
Although Boyd and colleagues found slightly stronger effects
with percentage breast density than with the dense area [15],
the dense area may be a better marker of breast cancer risk as
it is the absolute amount of glandular and stromal (dense) tis-
sue, which is regarded as the target tissue for breast cancer
Table 1
Basic characteristics of the study population (n = 775)
Age (years) 60.2 (5.4)
Height (cm) 163.7 (6.1)
Weight (kg) 69.7 (11.7)
Body mass index (kg/m2) 26.0 (4.1)
Waist–hip ratio 0.79 (0.06)
Family history of breast cancer (mother and/or sister with history of breast cancer) 106 (13.7)a
Reproductive factors
Age at menarche (years) 13.5 (1.7)
Nulliparous 99 (12.8)a
Age at first child birth(years) (among parous women only) 25.4 (4.0)
Number of children (average) (among parous women only) 2.6 (0.9)
Ever breast feeding(among parous women only) 558 (82.5)a
Age at menopause (years) 48.8 (4.9)
Time since menopause (years) 11.2 (6.8)
Lifestyle factors
Ever used oral contraceptives 416 (53.7)a
Ever used hormone therapy 112 (14.4)a
Time since stopped hormone therapy use (years) (among former hormone therapy users only) 7.1 (6.4)
Current smoking 171 (22.1)a
Ever smoked 421 (54.3)a
Alcohol intake (g/day) 8.1 (11.2)
Sex steroids and sex hormone binding globulin
Oestrone (pg/ml) 15.26 (4.38–53.16)b
Oestradiol (pg/ml) 8.22 (2.92–23.17)b
Free oestradiol (pg/ml) 0.24 (0.09–0.73)b
Dehydroepiandrosterone sulfate (ng/ml) 446.7 (102.3–1,949.8)b
Androstenedione (ng/ml) 0.46 (0.10–2.11)b
Testosterone (ng/ml) 0.25 (0.09–0.72)b
Free testosterone (pg/ml) 5.30 (1.46–19.23)b
Sex hormone binding globulin (nmol/l) 19.63 (5.21–73.96)b
Breast measures
Percentage breast density 21.7 (14.9–30.8)c
Dense area 25.3 (18.4–35.5)c
Nondense area 95.1 (70.1–121.9)c
Data presented as the mean (standard deviation), unless stated otherwise: an (%), bgeometric mean (± 2 standard deviations), cmedian 
(interquartile range).    Vol 9 No 4    Verheus et al.
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[27,28]. None of the previous studies on sex steroids and
breast density presented results for the nondense area, which
is part of the denominator to calculate the percentage breast
density.
In the present study, crude models show both oestrone and
oestradiol to be inversely related to the percentage density.
After correction for BMI these relations were no longer appar-
ent. Associations with free oestradiol were in the same direc-
tion and were somewhat stronger. Three other studies also
found the crude inverse relation between oestradiol and per-
centage density, but only in the study by Boyd and colleagues
did this association remain statistically significant after adjust-
ments for confounders, although only with free oestradiol
[15,18]. This inverse relationship appeared to be stronger for
the percentage density than for the absolute dense area. Aiello
and colleagues only presented results of multivariate analyses,
which showed oestrogens not to be related to percentage
density [16]. Only Greendale and colleagues found the oppo-
site result, with a positive association between oestrogen lev-
els and percentage density, which even became stronger and
statistically significant after correcting for confounding varia-
bles [14]. We do not know what caused this different finding
by Greendale and colleagues. A relatively large percentage of
their study population consisted of former HT users and the
average time since last use of these compounds was smaller
compared with other studies. It is not known what time period
is needed for a complete washout of the effect of exogenous
Table 2
Mean percentage breast density for quintiles of sex steroids and sex hormone binding globulin (n = 775)
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 P value for trend
Oestronea
Crude 24.7 (22.8–26.7) 22.6 (20.7–24.6) 22.0 (20.3–23.9) 22.3 (20.6–24.0) 20.1 (18.5–21.8) <0.01
+ BMI 23.6 (21.9–25.5) 21.8 (20.0–23.6) 22.3 (20.6–24.0) 22.6 (21.0–24.2) 21.2 (19.6–22.9) 0.12
Oestradiolb
Crude 24.7 (22.8–26.6) 23.4 (21.6–25.3) 20.8 (19.1–22.6) 22.5 (20.7–24.4) 20.2 (18.5–21.9) <0.001
+ BMI 23.1 (21.4–24.9) 22.5 (20.8–24.3) 20.7 (19.1–22.4) 23.1 (21.4–25.0) 22.0 (20.3–23.7) 0.58
Free oestradiolc
Crude 24.9 (23.1–26.9) 23.5 (21.7–25.4) 21.6 (19.8–23.4) 22.0 (20.3–23.8) 19.5 (17.9–21.2) <0.0001
+ BMI 23.1 (21.4–24.9) 22.5 (20.9–24.3) 21.5 (19.8–23.2) 22.6 (20.9–24.4) 21.6 (19.9–23.4) 0.34
Dehydroepiandrosterone sulfated
Crude 22.7 (20.9–24.6) 21.9 (20.1–23.8) 20.9 (19.1–22.7) 22.8 (21.0–24.6) 23.1 (21.3–25.0) 0.44
+ BMI 22.5 (20.8–24.3) 22.1 (20.4–23.8) 21.2 (19.5–22.9) 22.8 (21.1–24.6) 22.8 (21.1–24.6) 0.54
Androstenedionee
Crude 21.8 (20.0–23.7) 22.9 (21.0–24.7) 22.0 (20.2–23.8) 23.6 (21.8–25.5) 21.1 (19.4–22.9) 0.52
+ BMI 21.1 (19.5–22.9) 22.7 (21.0–24.4) 22.5 (20.8–24.3) 23.5 (21.8–25.3) 21.6 (19.9–23.3) 0.88
Testosteronef
Crude 23.2 (21.4–25.2) 23.8 (22.0–25.7) 22.2 (20.4–24.1) 21.7 (20.0–23.5) 20.5 (18.8–22.2) 0.01
+ BMI 21.9 (20.2–23.7) 23.4 (21.7–25.2) 22.2 (20.5–24.0) 22.1 (20.4–23.8) 21.7 (20.1–23.5) 0.48
Free testosteroneg
Crude 26.0 (24.1–28.0) 22.9 (21.1–24.8) 21.1 (19.4–22.9) 21.7 (20.0–23.5) 19.8 (18.1–21.5) <0.0001
+ BMI 24.2 (22.5–26.1) 22.1 (20.4–23.8) 21.0 (19.4–22.7) 22.5 (20.8–24.2) 21.6 (19.9–23.3) 0.13
Sex hormone binding globulinh
Crude 19.3 (17.6–21.0) 20.1 (18.5–21.9) 22.8 (21.0–24.6) 23.0 (21.2–24.9) 26.2 (24.4–28.2) <0.0001
+ BMI 21.4 (19.7–23.2) 20.8 (19.2–22.5) 22.4 (20.7–24.1) 22.4 (20.7–24.1) 24.4 (22.6–26.3) <0.01
+ BMI and WHR 21.9 (20.2–23.8) 21.4 (19.7–23.1) 22.2 (20.6–23.9) 22.2 (20.5–23.9) 23.7 (21.9–25.5) 0.11
Data presented as the mean (95% confidence interval). BMI, body mass index; WHR, waist–hip ratio. aQuintile cutoff points: 7.45, 12, 15, 20 and 
29 pg/ml. bQuintile cutoff points: 4.45, 6.4, 8.2, 10.0 and 14 pg/ml. cQuintile cutoff points: 0.12, 0.18, 0.24, 0.31 and 0.45 pg/ml. dQuintile cutoff 
points: 188, 333, 479, 666 and 1,041 ng/ml. eQuintile cutoff points: 0.19, 0.36, 0.50, 0.67 and 1.10 ng/m. fQuintile cutoff points: 0.13, 0.20, 
0.26, 0.33 and 0.47 ng/m. gQuintile cutoff points: 2.29, 3.98, 5.48, 7.50 and 11.36 pg/ml. hQuintile cutoff points: 6.2, 15, 21, 28 and 43 nmol/l.Available online http://breast-cancer-research.com/content/9/4/R53
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hormones on both endogenous sex steroid levels and breast
density. Results of ever users should therefore be interpreted
cautiously. In the present study, only 14% of the study partici-
pants were former HT users and the median time since last HT
use was 5 years (interquartile range, 2–10 years). When we
stratified the analyses to HT ever use, oestrogen levels were
significantly inversely related to both percentage breast den-
sity and dense area, which was not seen in the subgroup of
never HT users. The difference in effect between never HT
users and ever HT users was not seen with any of the other sex
steroids or SHBG, and the results with oestrone levels may be
chance.
Our result of a positive association between circulating SHBG
levels and the percentage breast density are in line with four
previous studies [14,15,17,18]. As in the present study, the
crude effect in most of these studies was very explicit, but
became weaker after correction for confounding factors, espe-
cially BMI or other measures of total body fat. In our study,
women with high SHBG levels had slightly, but nonsignifi-
cantly higher dense area and smaller nondense area. The
apparently positive association between SHBG levels and
percentage breast density or dense area seems in contradic-
tion with the inverse relation between these SHBG levels and
breast cancer risk that has been described in many epidemio-
logic studies [12,13]. A possible explanation was offered by
Greendale and colleagues, who suggested a difference in
SHBG-receptor-mediated effects between normal and can-
cerous breast tissue [14].
Studying so many associations raises the question of whether
multiple testing has resulted in false positive results. The pos-
itive crude relations between both oestrogens and testoster-
one and the nondense area, however, were expected. After
menopause, circulating oestrogen levels reflect the conver-
sion of androgens to oestrogens in adipose tissue. Most of the
circulating testosterone is also converted in the adipose tissue
from androstenedione [33]. Oestrogens and testosterone are
therefore strongly correlated with BMI, as is the nondense (fat)
area. These relationships also explain the crude inverse asso-
ciations between both oestrogens and testosterone with per-
centage density, as the nondense area is in the denominator
to calculate this relative measure of mammographic density.
After correction for BMI the relations between oestrogens and
testosterone and both the percentage density and the non-
dense area disappeared.
Circulating progesterone levels were not available in the
present study. As combined oestrogen and progesterone HT
use exerts stronger effects on breast density than oestrogen
alone treatment [34-37], progesterone levels may be associ-
ated with breast density. Although only one [15] of the four
studies [14,15,17,18] researching this association found a
significant increase in breast density, progesterone levels and
combined oestrogen and progesterone levels may affect
breast density.
Conclusion
After studying our results and the results of five previous stud-
ies on sex steroids and postmenopausal breast density, we
conclude that there is no major proof for such associations in
postmenopausal women, at least not to the same extent as the
associations between sex steroid levels and breast cancer
risk. Some of the previous studies were relatively small, but the
study by Warren and colleagues [18] as well as our own study
had enough power to detect such effects. The relationship
between sex steroids and breast cancer risk as described in
the literature does not seem to be explained by a change in
mammographic density.
Table 3
Mean dense breast area for quintiles of sex steroids and sex hormone binding globulin (n = 775)
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 P value for trend
Oestronea 27.4 (25.3–29.5) 27.3 (25.1–29.6) 27.0 (25.0–29.1) 26.5 (24.6–28.5) 25.2 (23.3–27.2) 0.09
Oestradiolb 27.9 (25.8–30.0) 27.7 (25.7–29.8) 24.3 (22.4–26.3) 27.2 (25.2–29.4) 26.1 (24.2–28.1) 0.27
Free oestradiolc 27.8 (25.7–29.9) 27.3 (25.2–29.4) 26.0 (24.0–28.0) 26.3 (24.3–28.3) 25.9 (23.9–28.0) 0.20
Dehydroepiandros
terone sulfated
27.8 (25.7–29.9) 26.0 (24.0–28.1) 26.5 (24.5–28.6) 26.2 (24.2–28.3) 26.7 (24.7–28.8) 0.68
Androstenedionee 26.8 (24.8–28.9) 27.1 (25.1–29.3) 25.5 (23.5–27.6) 28.2 (26.2–30.3) 25.5 (23.5–27.5) 0.44
Testosteronef 27.1 (25.0–29.2) 27.5 (25.5–29.6) 25.9 (23.9–28.0) 26.3 (24.3–28.3) 26.4 (24.4–28.5) 0.53
Free testosteroneg 28.7 (26.6–30.8) 25.6 (23.7–27.7) 25.3 (23.4–27.4) 27.5 (25.4–29.6) 26.1 (24.1–28.1) 0.36
Sex hormone 
binding globulinh
26.3 (24.2–28.4) 26.2 (24.2–28.2) 25.5 (23.6–27.5) 27.7 (25.6–29.8) 27.5 (25.5–29.7) 0.22
Data presented as the mean (95% confidence interval). aQuintile cutoff points: 7.45, 12, 15, 20 and 29 pg/ml. bQuintile cutoff points: 4.45, 6.4, 
8.2, 10.0 and 14 pg/ml. cQuintile cutoff points: 0.12, 0.18, 0.24, 0.31 and 0.45 pg/ml. dQuintile cutoff points: 188, 333, 479, 666 and 1,041 ng/
ml. eQuintile cutoff points: 0.19, 0.36, 0.50, 0.67 and 1.10 ng/m. fQuintile cutoff points: 0.13, 0.20, 0.26, 0.33 and 0.47 ng/m. gQuintile cutoff 
points: 2.29, 3.98, 5.48, 7.50 and 11.36 pg/ml. hQuintile cutoff points: 6.2, 15, 21, 28 and 43 nmol/l.Breast Cancer Research    Vol 9 No 4    Verheus et al.
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